
IQVIA Hlds (IQV) Stock Forecast & Price Target
IQVIA Hlds (IQV) Analyst Ratings
Bulls say
IQVIA Holdings has demonstrated robust growth across its segments, particularly in Functional Service Provider (FSP), Real World Evidence (RWE), and Clinical Sales and Marketing Services (CSMS), all recording year-over-year growth in the third quarter. The company is experiencing improved client decision timelines and a strong pipeline, primarily fueled by recent drug launches, positioning it well for continued commercial momentum. Additionally, IQVIA's confidence in achieving over 4% growth in its Research & Development Services (R&DS) segment, coupled with an improved pricing environment allowing the company to optimize deal selection, underscores its positive financial outlook.
Bears say
The financial outlook for IQVIA Holdings reflects a concerning slowdown in year-over-year constant currency (CC) growth, declining from 6.8% in 2Q25 to 3.8% in 3Q25, particularly due to challenging comparisons from the prior year. Despite the company’s assertions of confidence regarding future revenue growth, the expectation of at least 5% growth in 2026, combined with operational challenges related to passthrough margins and increasing interest rates, could exert further pressure on earnings. Additionally, the disparate growth rates among segments, particularly the slower rates in the Technology and Analytics Services (TAS) and Research and Development Services (R&DS) segments, highlights potential vulnerabilities in sustaining overall revenue momentum.
This aggregate rating is based on analysts' research of IQVIA Hlds and is not a guaranteed prediction by Public.com or investment advice.
IQVIA Hlds (IQV) Analyst Forecast & Price Prediction
Start investing in IQVIA Hlds (IQV)
Order type
Buy in
Order amount
Est. shares
0 shares